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Abstract 
Conjugating cytotoxic agents to antibodies allows for site-specific delivery of the agent to tumor cells 
and should provide increased efficacy and reduced non-specific toxicity. These site-specific cpotogc agents 
are known as irnmunoconjugates or "magic bullets" and have demonstrated great promise as therapeutic 
agents for cancer and other diseases. The historical developments and future potential of this new approach 
to cancer therapy are reviewed. 
Introduction 
Cancer is responsible for approximately twenty-five percent of the deaths in industri&zed countries 
and it is estimated that there are currently over seven million cancer patients in America. The Amer im 
Cancer Society estimates that over one million Americans will be diagnosed with cancer in 1992 and that 
approximately 520,000 people will die of cancer, making it the second leading cause of death in . h e r i a .  
Despite these alarming statistics, anticancer therapeutics account for only the eighth-largest pharmaceutid 
market in the United States. 
Cancer causes far more morbidity and mortality than diseases that account for far larger drug 
markets and has shown much slower market growth. The slow market growth for the cancer therapeutic 
market is primarily because of the problems associated with low efficacy and the serious side effects of the 
majority of anticancer drugs. Even the most effective drugs, including some biotherapies, show as Etde as a 
fifty percent success rate. In addition, most cancer therapy is extremely toxic since chemotherapeutic agents 
kill normal cells as well as cancer cells. 
Cancer therapies have historically consisted primarily of surgery, chemotherapy, and radiation. 
Because of the risks and invasive nature of surgery, and the adverse effects of radiation and cbeimotlherapy, 
there is tremendous opportunity for new non-invasive therapies which offer improved efficacy while reducing 
associated side effects. Recent advances have provided opportunities for developing new alternative treatment 
strategies. One approach is to target a cytotoxic agent to the cancer cell through the development of 
immunoconjugates. The term immunoconjugate designates monoclonal antibodies (or antibody framents 
containing their binding sites) linked to cytotoxic agents: drugs, toxins, radioisotopes or cytotoic cells of the 
immune system. To accomplish this, the cytotoxic agent is attached to an antibody or a growth factor that 
preferentially binds to cancer cells. 
This exciting new technology has proven to be a feasible alternative to conventional chemothempry 
and shows promise as an effective therapy for many cancers which have not responded well to conventional 
therapies. According to a 1991 Frost & Sullivan market report, the market for cancer therapy 
immunoconjugates is projected to be approximately $720 million by 1996 and should continue to p o w  as 
technological improvements provide for higher clinical efficacy and general market acceptance [I]. 
This article will review the progress as well as several problems inherent to this approach to cancer 
therapy, and briefly highlight approaches taken at the NIH and elsewhere to advance this techolaar. 
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Historical Background and Current Developments 
About 1913, Paul Ehrlich conceived the idea of therapeutics which function as "magic bullets* [2]. 
EhrLc&a's 'magic bulletsn combined the targeting properties of antibodies with cytotoxic agents. Nearly eighty 
years later, this vision is be ng to reach fruition. The protracted period between Ehrlich's conception 
and the potential realization of immunoconjugate therapy for certain cancers underscores the numerous 
technolo@cd aficulties encountered in this field. 
The first consideration in developing a "magic bulletn for cancer therapy is selection of an 
appropriate carrier or targeting agent to deliver toxic agents specifically to the tumor cells. In theory, the 
targeting agent could be any moiety capable of selective biding to a receptor on tumor cells. Indeed, anti- 
tumor reagents have been produced by attaching cytotoxic agents to numerous cell recognition proteins, 
including antibodies, alpha transforming growth factor, epidermal growth factor, interleukiis, and transferrin 
[3,4jj. Site-directed cytotoxicity is aimed primarily at cell-surface antigens or at receptors expressed in high 
numbers on m c e r  cells or other cells of interest. Toxic substances can be conjugated to antibodies or fusion 
proteins that recognize the cell-surface antigens characteristic of the specific cell type that is targeted for 
treatment. The toxin complex then specifically binds to the targeted cells resulting in a localized high dose of 
the toxin to them while sparing the normal cells. Early attempts to develop "magic bulletsn using polyclonal 
antisera against turllor cells were frustrated by significant cross reactivity with surface antigens on normal 
cells. Even after rigorous absorption against normal tissues, polyclonal antisera preparations vary markedly 
in reacti.iiity, specificity, and reducibility [5]. Coupling cytotoxic agents to such antibodies exacerbates the 
non-specificiq? and results in therapeutic preparations with unacceptable toxic side effects. 
Development of antibodies specific to tumor cells was revitalized with the introduction of hybridoma 
technolo@ in 1975 which permits production of monoclonal antibodies against a selected antigen [6]. 
Despite this significant advance over polyclonal antisera, many monoclonal antibodies to tumor cells retain 
some degree of cross-reactivity with normal cells. Anti-tumor immunotoxic conjugates displaying cross- 
reacti~ty to normal tissue must be employed judiciously to minimize toxic side effects. The search for new 
monoclonals ~ 4 t h  greater specificity against tumor cells is an ongoing endeavor. For example, NIH scientists 
have patented or have pending patent applications claiming an expanding portfolio of selective monoclonal 
antibodies useful for treating a wide variety of cancers, including medulloblastoma, glioblastoma, 
adenocarcinomas, squamous cell carcinomas, breast, colon, prostatic, ovarian, cervical, and esophageal 
cancer, 
Most currently available monoclonals against tumor cells are derived from murine hybridomas. 
Multiple administration of such monoclonals stimulates immunological responses by the human host against 
the foreign mouse immunoglobulins [7]. Neutralizing human anti-mouse antibodies compromise the efficacy 
of imrnunoconjugate therapy. The ultimate solution to this problem, of course, would be to utilize human 
monoclond antibodies rather than murine species. Progress continues in the developing field of human 
hybridoma technology. A group from the National Cancer Institute and Bionetics Research (a division of 
Organon-Teknika) has reported testing the immunogenicity of conjugates incorporating two human 
immunoglobaaBirns directed against colorectal cancer. To date, the study has confirmed the general 
expeckation that immunogenicity of human antibodies will be low [I]. However, nagging technical problems 
remain with establishing human hybridomas which prevent them from being a reliable source of human 
mongac8onals in the near term. 
In lieu of human hybridomas, much work has been directed toward "humanizing" murine monoclonal 
antibodies. A simple technique which markedly reduces anti-mouse immunoglobulin effects is to use only 
those portions of the immunoglobulin molecule responsible for binding affinity and specificity. Consequently, 
immunoconjugates have been constructed using Fab, Fab' or F(ab')2 fragments rather than intact 
immunoglobulin [8]. This eliminates the immunogenic epitopes of the Fc region of the mouse antibody. 
Two additional benefits may accrue from removal of the Fc portion of the antibody. Firstly, large 
hmunao@obulh conjugates have difficulty permeating solid tumors. This problem is reduced substantially 
when smaller antibody fragments are employed. Secondly, such fragments eliminate non-specific binding to 
non-target cells mediated via the Fc region; e.g., binding to cells of the reticuloendothelid system. These 
potential benefits must be weighed against negative consequences of using antibody fragments. For emmpIe, 
antibody fragments are known to be cleared from circulation more quickly than intact immune~obulins [9]. 
Additionally, Fab fragments would not be indicated in situations where the Fc portion of the mtibody is 
critical to the biological function of the antibody. For example, Michael er of the Nationd IrastHtkate of 
Allergy and Infectious Diseases has developed a model for selective destruction of cells expresskg high 
affinity IgE Fc receptors (e.g., mast cells in either malignant systemic or benign systemic mastocposis) 
employing IgE immunotoxin conjugates [lo]. 
Another approach to "humanize" murine monoclonals for human therapy relies upon appGcation of 
recombinant DNA technology. Chimeric (or mouse/human) antibodies have been created whereby the 
constant regions of human immunoglobulins are fused to the variable regions of mouse monoclonal 
antibodies I l l ] .  These chimeric antibodies retain the antigen binding specificity of the mouse monocBond, 
elicit reduced human anti-mouse antibody responses in patients, and are not subject to the enhanced 
clearance rates of Fab fragments. 
An exquisite extension of the recombinant approach involves constructing mouse/human chimeric 
antibodies which incorporate only the complementarity-determining regions (CDRs) from the mouse, CDRs 
are the portions of the antibody molecule which guide the antibody to its binding ligand. The remainder of 
the chimeric antibody structure is human, including the framework residues (FX) which support the CDRs 
and determine the disposition of the CDRs relative to one another 1121. A further variation on this 
technique, called "veneering", was developed as a joint invention by Merck & Co., Inc. and Eduardo Padlan 
of the National Institute of Diabetes and Digestive and Kidney Diseases. Veneering judiciously replaces 
mouse exterior amino acid residues in the variable region of the antibody with those of the human. The 
premise of "veneering" is that the key residues in CDRs (i.e., those involved in preserving ligawd binding) are 
n -  
mterior" and interdomain contact residues. Consequently, surface amino acid residues of mouse origin, 
which can be "seen" by the immune system in its immune surveillance, may be changed to their human 
counterpart without affecting ligand binding properties. 
Selection of appropriate and optimal cytotoxic components for immunoconjugates also lhas been an 
area of active research. Early anti-tumor immunoconjugates combined antibodies with know low molecular 
weight chemotherapeutics such as radionuclides, DNA alkylating agents, and anti-metabolites. Recently, 
Otto Gansow of the National Cancer Institute has reported encouraging results using yttrium-W conjugated 
to anti-interleukin-2 receptor antibody for treating T-cell leukemia patients. The greatest interest, however, 
has been in the use of bacterial and plant toxins as the cytotoxic element of therapeutic kmmunoconjugaites. 
The best studied of these toxins are diphtheria toxin (DT) from Co~nebacterium diphfheia, the nectin ridn 
from the seeds of Ricinus communis, and pseudomonas exotoxin A (PE) from Pseudomonas aeasrgnosa. 
Both DT and ricin are heterodimeric molecules consisting of A-and B-chains. In both toxi~as, the B- 
chain is responsible for cellular binding and entry into the target cell, and the A-chain is a potent inhibitor of 
protein synthesis. DT bound to cell surfaces by the B-chain enters the cell via receptor-mediated 
endocytosis. Within the resulting endosomes, the B-chain of diphtheria toxin undergoes a conformational 
change which permits the A-chain to translocate into the cytoplasm. Once in the qoplasm, diphtheria toxin 
A-chain irreversibly inhibits the protein translation machinery. Specifically, A-chain inactivates elongation 
factor 2 (EF-2) via an ADP-ribosylation reaction. Ricin binds to cells via affinity of its B-chGn for ttermbai 
galactose residues of cell surface glycoproteins and glycolipids. Analogous to diphtheria toxin, swface-bound 
rich becomes internalized within vesicle structures, and the B-chain facilitates the translocation of the rich 
A-chain ("ricin An) out of vesicles into the cytoplasm. Ricin A inhibits protein synthesis via selective N- 
glycosidase activity which cleaves a specific adenine residue in the 28s ribosomal subunit. Both toxins we 
extremely potent: a single molecule is sufficient to inhibit protein synthesis within a cell. 
Both DT and ricin have been conjugated to antibodies producing immunotoxins with potent cytotoAc 
activities [13]. Such immunotoxins, however, exhibit serious non-selective binding due to the binding 
properties of their respective B-chains. Attempts to remedy this problem by conjugating only the A-chain of 
the toxin to the antibody produces immunotoxins with good selectivity, but variable cytotoxic potency [14]. 
Genes for both diphtheria toxin and ricin have been cloned, and recombinant constructs containing mutant 
B-chains are being tested for reduced cell biding. Richard Youle and colleagues at the National Institute of 
NeuroBo@cd Disorders and Stroke have developed a recombinant DT with reduced cell binding properties 
[15]. W e n  conjugated to anti-human transferrin receptor or anti-CD3 antibodies, this recombinant DT 
demonstrated up to 1,000 fold reduction in cell binding; yet was equal to wild-type immunotoxin in cytotoxic 
potency. David Neville's research group at the National Institute of Mental Health has developed similar 
immunotofis utilizing recombinant DT. 
h o t h e r  hmunotoxin system demonstrating exceptional promise has been developed in Ira Pastan's 
laboratory at the National Cancer Institute. This system utilizes the bacterial toxin pseudomonas exotoxin A 
(PE). Analogous to the B-and A-chains of DT and ricin, PE contains domain I and domain I11 which confer 
cell bindmg and cytotoxicity, respectively 1161. Cytotoxicity is accomplished by the same mechanism as in 
diphtheria to& i.e., ADP-ribosylation of elongation factor 2. Unlike rich and DT, pseudomonas exotoxin A 
additiona1ly has a domain I1 which mediates translocation of the toxic domain I11 across cell membranes. 
Consequently, it has been possible to abolish cell binding (i.e, domain I function) without disturbing 
membrane translocation functions [17]. Recombinant pseudomonas exotoxins, with truncations in domain I 
(PE4-0 and PIE%), have been prepared. These modified forms of pseudomonas exotoxin are as potent as 
native PE, but are 100 fold less toxic to nontarget cells [3,18]. 
P E 4  and PE38 have been used also to construct completely recombinant immunotoxins by fusing 
them to DNA fragments encoding growth factors, antibodies, and antibody-fragments. In this way, PEN and 
PE38 have been joined to the carboxyl end of the fragment variable (Fv) portion of antibodies to produce, so 
called, "recombinant single chain immunotoxins". The Fv region is the smallest antibody fragment capable of 
binding antigen. They consist of two chains, each about 110 amino acids in size, held together by a linking 
peptide about 15 amino acids in length. Recombinant single chain immunotoxins have been constructed to 
selectively bind the human transferrin receptor, human IL-2 receptor, and an antigen, recognized by 
monoc?onal antibody B3, found on many human carcinomas (e.g., prostate, colon, stomach, breast, ovary, 
lung, and bladder). These recombinant immunotoxins are particularly attractive in that they can be produced 
in large amounts in E. coli, have reduced animal toxicity, and appear to be well suited to penetrate solid 
tumors by virtue of their small size [19-211. 
Tbe application of recombinant toxins has markedly reduced toxic side effects associated with the 
native molecules. These still are foreigsl proteins, however, and repeated administration leads to host 
immunolo~ca~ responses against the toxin. Richard Youle's laboratory has developed an approach to further 
"humanize" immunotoxins. They constructed a recombinant immunotoxin, where the traditional bacterial or 
plant toxin is replaced by a human enzyme, angiogenin [22]. Angiogenin is a protein found in normal blood 
pibasma, and has homology to pancreatic Rnase. While not cytotoxic toward intact cells, angiogenin is a 
potent inhibitor of protein synthesis once it gains access to the protein synthesis machinery within the 
cyoplasm. Attachment of angiogenin to antibodies directed against cell surface antigens results in 
endocflotic incorporation, followed by inhibition of protein synthesis. Using recombinant techniques, 
angogenin was fused to a mouse/human chimeric antibody heavy chain gene. This antibody-angiogenin 
ifusion protein was introduced into a transfectoma which secreted the chimeric light chain of the same 
antibody [23]. The resultant F(ab') like antibody-angiogenin fusion protein has the "magic bullet" properties 1- 
of antibodies linked to plant/bacter~al toxins, but elicits a reduced immune response in the host. 
&so, recent studies are beginning to demonstrate synergistic antitumor effects when 
immuaoconjugates are used in conjunction with other treatment modalities. Because of the advantages of site 
directed specificity and the potential for synergistic effect, immunoconjugates are expected to replace or 
supplement, in increasing measure, the use of unconjugated chemotherapeutics and radionuclides in 
therapy [I]. 
Market Outlook 
The primary criteria for an immunotoxin are specificity and high potency, i.e, the toxin must be 
delivered to a specific cell type and must be able to get into the cells for maximum cytotoxic effect, The 
immunotoxin market is currently dominated by the use of one of three toxins, i.e., ricin toxin, pseudomiimonas 
exotoxin, and diphtheria toxin. 
Although irnmunoconjugates show much promise for cancer therapy, they will certainly not replace 
surgery as the primary therapy whenever surgery is feasible. Even when it is known that not dl m d p a n t  
sites can be resected, it is important to decrease the tumor burden as much as possible, so that the non- 
invasive treatments, and the patient's own defenses, have a reduced task. Large tumor masses, .uv$ich are 
most amenable to surgical resection, are also least accessible to conjugates and other pharmaeolo~d  agents, 
because of their poor internal circulation [I]. Immunoconjugate therapy will most likely be the p r h q  
therapy of choice for inoperable cancers and for cancer micro-metastases, i.e., when cancerous cells mwe to 
various locations throughout the body. 
Currently, the major obstacle to overall market acceptance of immunotoxins for therapeutic applications is 
non-specific toxicity. Price is also an obstacle: initially the cost will be $2,000 - $5,000/course of treatment 
for therapeutic immunoconjugates [I]. This increased cost for treatment may however, be justified by the 
decrease in required hospital care, i.e,. the immunoconjugate therapies may prove to be more effective and 
efficient for treating numerous diseases with fewer side effects, and consequent faster discharge from the 
hospital. 
m a t  role immunoconjugates will play in future cancer therapies is not yet clear, but in solid tumors 
therapeutic immunoconjugates will probably be most useful for eliminating residual or occult sites of 
malignancy after surgery, and to reduce the tumor burden, prolong life and improve the qua&@ of Cfe for 
patients with advanced disease [l]. 
Immunoconjugate therapy is most obviously applicable to cancer therapy, but may have si@fimt 
market penetration in numerous other therapeutic applications including: rheumatoid arthritis, diabetes, 
infectious diseases, AIDS, and graft vs. host disease. 
Scientists at the NIH have played a major role in the development of this promising technolo~ and 
continue to be at the forefront of new discoveries in the fight against cancer. These new developments are 
brought forward to the market place through the patenting and licensing efforts of the Office of Techoloa 
Transfer at NIH. Technology transfer is the process by which the 
discoveries of laboratories are brought forth into practical knowledge and useful products. The MH Office 
of Technology Transfer's primary mission is to facilitate the transfer of technology from Federd laboratories 
into the private sector for further development and commercialization for the benefit of world healtb 
It is critical to the medical community and the public welfare that these new technologies find their 
way to the market place as quickly and safely as possible. The continued efforts of NIH scientists have 
resulted in major advances. Through the technology transfer process, the promise of "magic bullets" appears 
closer to realization. 
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